Nasdaq GlobeNewswire

UPDATE -- Eloxx Pharmaceuticals Appoints Robert Ward Chairman and Chief Executive Officer

Del

Biopharmaceutical Industry Leader with Extensive Experience In Drug Development, Strategic Business Combinations and Commercialization to Lead The Company's Strategy, Vision and Execution

WALTHAM, Mass., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. ("Eloxx") (OTCQB:SVOND), a clinical-stage biopharmaceutical company developing novel small molecule medicines to treat rare and ultra-rare genetic diseases caused by nonsense mutations today announced that Robert ("Bob") Ward has been appointed Chairman of the Board of Directors of Eloxx (the "Board") and Chief Executive Officer effective immediately. Bob succeeds outgoing Chairman of the Board, Robert Heft, and current founder and Chief Executive Officer Dr. Silvia Noiman at a critical inflection point for Eloxx as the company advances its lead candidate ELX-02, a novel translational read-through inducing drug (TRID), through the completion of Phase 1 clinical trials and navigates its transition from a private to a public company.

Mr. Ward brings to Eloxx more than 30 years of experience as a global biopharmaceutical industry leader with experience across the full spectrum of drug development, commercialization, and strategic business development transactions. Mr. Ward most recently was the President and Chief Executive Officer of Radius Health, Inc. ("Radius").

"We are pleased to have attracted an experienced leader with Bob's proven track record of success to Eloxx," said Dr. Robert Heft.  "Having previously lead a fully integrated commercial biopharmaceutical company to achieve its first drug approval and product launch, we are confident that Bob is the right leader to advance Eloxx as we seek to develop and commercialize our novel small molecule medicines to treat rare and ultra-rare genetic diseases."

"Bob has already built substantial value for patients, employees, and shareholders through his management of the development and commercialization of important drugs, transformative business development transactions and substantial financings," said Dr. Noiman. "As a fellow Board member, I look forward to working with Bob during the transition as we advance our pipeline and build Eloxx."

"I am excited to have the opportunity to lead Eloxx and build upon the successful work of Drs. Heft and Noiman. Today the Company is poised to accelerate our portfolio and to potentially improve the lives of patients with rare diseases while continuing to build our Company and create substantial value for shareholders and our employees," said Mr. Ward. "We are grateful for Dr. Heft's service and many contributions to the Board and our shareholders."

Mr. Ward was formerly the President and Chief Executive Officer of Radius, where he helped the company successfully complete its Initial Public Offering in 2014, and lead the development, approval and launch of the company's TYMLOS(TM) injection. He is a global pharmaceutical industry leader managing all stages of drug development, commercialization, and strategic deal making and partnerships across multiple therapeutic areas. Prior to joining Radius, Mr. Ward was Vice President for Strategy and External Alliances for the New Opportunities iMed of Astra Zeneca from 2011 to 2013. He has held a series of progressive management and executive roles with established companies such as NPS Pharmaceuticals, Schering-Plough (Merck), Pharmacia (Pfizer), Bristol-Myers Squibb and Genentech. Mr. Ward has been a Director of Akari Therapeutics, Plc since October 14, 2016. He served as a Director of Radius from December 2013 until July 16, 2017. Mr. Ward serves as a Director of the Massachusetts High Technology Council. Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara, an M.S. in Management from the New Jersey Institute of Technology and an M.A. in Immunology from the John Hopkins University School of Medicine.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. Nonsense mutations are a class of genetic defects that result in premature termination of protein synthesis. These nonsense mutations have been identified in over 2,000 rare and ultra-rare diseases.  As a consequence, patients with a genetic disease caused by nonsense mutations have absent or truncated nonfunctional proteins, accounting for some of the most severe phenotypes in these genetic diseases. Eloxx's lead product candidate, ELX-02, is an investigational, novel translational read-through inducing drug designed to restore synthesis of full-length functional proteins. ELX-02 is an investigational agent undergoing clinical trials and has not been approved by any global regulatory body. Eloxx was founded in 2013 and is headquartered in Waltham, MA. with R&D operations in Rehovot, Israel.

Forward-Looking Statements

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a number of risks and uncertainties. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the Company's ability to continue as a going concern; the ability of the Company to consummate additional financings; the development of the Company's antibody technology; the approval of the Company's patent applications; the Company's ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company's research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company's products; the timing and success of the Company's preliminary studies, preclinical research and clinical trials; competition and the timing of projects and trends in future operating performance; and the quotation of the Company's common stock on an over-the-counter securities market, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update or revise such forward-looking statements to reflect subsequent events or circumstances.

Contacts:
Eloxx Pharmaceuticals
Greg Weaver, CFO
greg@eloxxpharma.com

Or

Barbara Ryan
Barbara Ryan Advisors
b.ryan12@me.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Eloxx Pharmaceuticals via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Nitinat Provides Progress Report on Carscallen and Jasper Properties23.4.2018 22:38Pressemelding

TORONTO, April 23, 2018 (GLOBE NEWSWIRE) -- Nitinat Minerals Corp. (the "Company") (TSXV:NZZ) (Frankfurt:04U1) is pleased to announce that the work on its 100% owned Carscallen Property is underway and is going as planned. The Corporation will be providing details on an ongoing basis as the work progresses and details become available. The Corporations is also pleased to announce the initiation of a work program on its 100% owned Jasper Property which is located inland from the western shore of Vancouver Island, B.C., roughly 80 kilometers Northwest of Victoria, lying in the area of Nitinat Creek and Lake and is accessed by logging roads coming in from the North. The Jasper Property consists of the Jas 3 legacy mineral claim and eight unnamed cell mineral claims that together comprise nine contiguous claims that cover 3978 hectares. The Jasper Property is 100% owned and operated by the Company. The Highly Visible mineralized showings on the Jasper claims lie in a rugged forested area a

Atico Reports Consolidated Financial Results for 201723.4.2018 22:30Pressemelding

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, April 23, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSX-V:ATY) (OTC:ATCMF) today announced its financial results for the year ended December 31, 2017, posting income from mining operations of $15.32 million and a net income of $4.04 million. Production for the year at Atico's El Roble mine totaled 20.6 million pounds ("lbs") of copper and 10,923 ounces ("oz") of gold in concentrates at a cash cost(1) of $1.45 per payable pound of copper produced(2). Fernando E. Ganoza, CEO and Director, commented, "We are pleased to report our strongest year to date both operationally and financially, as the Company concluded 2017 exceeding nearly all set objectives for the year. Operationally, we delivered above our higher end guidance while further increasing operational standards at El Roble. Financially, we have delivered a record year in most metrics while significantly s

Luxoft Develops 'Blockchain Adapter' for a Business Process Management Tool on Appian's Platform23.4.2018 21:58Pressemelding

Luxoft to unveil healthcare use case for blockchain adapter at Appian World in Miami, April 23-25 (Booth 16) Zug, SWITZERLAND and Reston, VA -- 24 April, 2018 - Luxoft Holding Inc. (NYSE:LXFT), a global IT service provider, today announces it has built a blockchain adapter for Appian's (NASDAQ:APPN) rapid application development platform. It is now available exclusively to businesses using Appian's Business Process Management (BPM) tool and will allow its users to integrate a blockchain network into their day-to-day business processes, creating a secure, digital environment that facilitates data sharing. "The launch of this adapter is about helping businesses realise the potential of blockchain by making it easier to use," said Vasiliy Suvorov, Vice President of Technology Strategy at Luxoft. "Problems integrating blockchain into existing in-house systems are often the biggest obstacles to its adoption. Now, by integrating blockchain into a BPM, a business can leverage the benefits of

Mitratech Acquires ThinkSmart LLC to Create Industry-First, End-to-End Legal Operations Platform23.4.2018 17:00Pressemelding

Integration of ThinkSmart's agile workflow software into Mitratech's TeamConnect platform sets a new global standard for legal and compliance innovation and excellence LAS VEGAS, April 23, 2018 (GLOBE NEWSWIRE) -- Today, Mitratech a leading provider of legal and compliance software, announced the acquisition of ThinkSmart LLC, creating an end-to-end platform designed to transform legal operations into a center of innovation and excellence. With the addition of ThinkSmart and the ThinkSmart Automation Platform (TAP), Mitratech's TeamConnect platform can now bring people, processes and information together like never before, by leveraging TAP's easy-to-use workflow automation engine to extend TeamConnect's reach across the entire enterprise. In today's rapidly evolving legal landscape, there is a need for a truly evolutionary Enterprise Legal Management (ELM) platform. ELM systems have delivered on the operational efficiencies, centralized view of information, security and data integrity

Vricon unveils new solution at GEOINT 2018: Vricon Precision 3D Registration (P3DR)23.4.2018 16:20Pressemelding

Precise, accurate, georegistered GEOINT data for analytics and visualization-at a global scale McLean, Virginia, April 23, 2018 (GLOBE NEWSWIRE) -- Vricon is pleased to announce that it is unveiling the next in a series of GEOINT solutions - Vricon Precision 3D Registration (P3DR) - at this year's GEOINT 2018 Symposiumin Tampa, Fla. Vricon P3DR is a software suite designed to automatically georegister imagery, regardless of collection platform, against the most accurate 3D geospatial foundation available, The Globe in 3D. P3DR can be implemented as a real-time processing workflow for imagery feeds without the need for GPS location, heading information, or ground control points. "While we've always been able to perform georegistration of individual data sets using our 3D models as an accurate foundation, Vricon P3DR takes this capability to a whole new level," said Magnus Brege, Vricon CEO. "Our users now have multiple options for where and when they can automatically georegister their

Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA23.4.2018 14:15Pressemelding

First Gene Therapy Using AAV Approach Granted Regenerative Medicine Advanced Therapy Designation NEW YORK and CLEVELAND, April 23, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ABO-102, the Company's AAV-mediated gene therapy for the treatment of Sanfilippo syndrome Type A (MPS IIIA), a rare autosomal-recessive lysosomal storage disease. "We are encouraged to have received the first gene therapy RMAT designation in MPS IIIA and look forward to further collaborating with the FDA to determine next steps in the development pathway for ABO-102," said Carsten Thiel, Ph.D., CEO of Abeona Therapeutics. "This action further reinforces the clinical significance in the data observed in the ongoing P

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom